China Traditional Chinese Medicine Holdings Co. Limited
0570Company Overview
China Traditional Chinese Medicine Holdings Co., Ltd. (“Chinese Traditional Chinese Medicine” for short) is the core platform for the Chinese medicine industry sector of China Pharmaceutical Group Co., Ltd. (“Sinopharm Group”). The company is listed on the main board of the Hong Kong Stock Exchange (stock code: 00570.HK), and its headquarters management center is located in Foshan, Guangdong. The company employs about 18,000 people and has over 100 subsidiaries. The company has a complete industrial chain, integrating scientific research, manufacturing and sales. It has more than 800 finished drug regulations (of which more than 280 product regulations were selected for the 2018 edition of the “National Essential Medicines Catalogue”), more than 700 varieties of single-flavor traditional Chinese medicine formula granules, and more than 400 classic compound concentrated granules (exclusively for export). It covers fields related to the cultivation of Chinese herbal medicines, traditional Chinese medicine tablets, formula granules, proprietary Chinese medicine, traditional Chinese medicine and health. Chinese traditional Chinese medicine brings together the essence of traditional Chinese medicine, spans more than 400 years of history, and inherits the famous names of “Liang Zhonghong Lavan”, “Feng Liangsheng”, “Tongjitang”, and “Yuanji Lin”, etc., and has the three time-honored Chinese brands “Feng Liangsheng,” “An Ning,” and “Tongjitang,” “Fairy Ling,” “Tongjitang”, “Xianling Bone Bao”, “Tianjiang Pharmaceutical”, and “German Zhong”, 5 famous trademarks, “Tongjitang Traditional Chinese Medicine Culture”, “Tongjitang” The four intangible cultural heritages of “Feng Liao's Rheumatism Medicated Liquor”, “Shaolin Pain Relief Cream”, and “Yuanji Gan He Tea”, as well as “Xianling Bone Bao Capsule” and “Neck Relaxation” “Granules,” “Rheumatoid Bone Pain Capsules,” “Seven Centigrade Capsules,” “Moisturizing and Itching Capsules,” “Zao Kernel Anshen Capsules,” “Yu Pingfeng Granules,” “Rhinitis Health Tablets,” “Golden Leaf Detox Granules,” and “Turtle Family Decontamination Pills” are the top 10 nationally exclusive essential medicines. Chinese traditional Chinese medicine has always insisted on quality as the core, has high-quality brands and product resources, and has won the trust of doctors and patients! With the mission of “implementing the national traditional Chinese medicine development strategy and leading the high-quality development of the traditional Chinese medicine industry”, the company will vigorously develop the herbal medicine resource industry with industry as the lead, science and technology as support, give full play to traditional trade advantages, actively enter the field of traditional Chinese medicine value-added health services, share the 10 billion traditional Chinese medicine platform with all sectors, and become a leader in the traditional Chinese medicine industry! Announcement on December 25, 2018: Wang Xiaochun assumed the position of president. Announcement on September 10, 2021: Wang Xiaochun was removed from the post of President. May 23, 2022 Announcement: Chen Yinglong will serve as Chairman of the Board of Directors.
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
This stock does not meet all Shariah compliance criteria according to AAOIFI standards.
Name | China Traditional Chinese Medicine Holdings Co. Limited |
Ticker | 0570 |
Main Business | Drug Manufacturers—Specialty & Generic |
Type | Common Stock |
Industry | Drug Manufacturers—Specialty & Generic |
Country | HK |
Market Cap | $2.54 B |
Shariah Analysis Breakdown
Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
---|---|---|---|
region | $3,510.0 | $0.0 | - |
Tianjiang River | $2,740.0 | $0.0 | - |
worldwide | $2,030.0 | $0.0 | - |
Tongji Hall | $1,020.0 | $0.0 | - |
Interest income | $67.3 | $67.3 | - |
Total | $9,367.3 | $67.3 | 0.71% (passed) |
Liability Item | Value ($M) | % of Market Cap |
---|---|---|
bank loans and overdrafts | $296,918,767.5 | 11.69% |
long term bank loan | $127,984,593.8 | 5.04% |
convertible notes and bonds | $168,067,226.9 | 6.62% |
Total Interest-Bearing Debt | $592,970,588.2 | 23.35% |
Market Capitalization | $2,539,384,615.4 | 100.00% |
Compliance Status | Threshold: 33% | passed |